Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.19.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Operating Activities:      
Net loss $ (12,687) $ (10,583) $ (1,234)
Adjustments to reconcile net loss to net cash used in operating activities:      
Gain on warrants [note 8 and note 12[e]]   (150)  
Depreciation 60 59  
Amortization 222 223 223
Stock-based compensation [note12[c]] 854 348  
Deferred income tax (recovery) [note 2 and 5]   (3,051) (504)
Bargain purchase gain [note 2]   (1,272)  
Loss on disposition [note 2]   8,610  
Contingent value rights recovery [note 2]   (200)  
Changes in operating assets and liabilities:      
Amounts receivable 2 (9)  
Prepaid expenses and other assets (343) (1,349) (2)
Accounts payable (69) 118 22
Accrued liabilities other 310 (2,185) 670
Accrued clinical liabilities 322 877  
Accrued compensation 710 458  
Salaries payable   (1,028) 623
Lease obligation (4) 27  
Net cash used in operating activities (10,623) (9,107) (202)
Financing Activities:      
Proceeds from share subscription   64  
Proceeds from purchase agreement with Lincoln Park Capital, net of issuance costs 1,279 1,942  
Proceeds from June 2018 public offering, net of issuance costs 12,194    
Proceeds from exercise of warrants, net of issuance costs 1,324    
Proceeds from October 2018 registered direct offering, net of issuance costs 4,960    
Taxes paid related to net share settlement of equity awards   (5)  
Stockholder loans     150
Net cash provided by financing activities 19,757 2,001 150
Investing Activities:      
Cash received on reverse takeover of OncoGenex   12,648  
Purchase of property and equipment (46)    
Proceeds on disposal of assets 10    
Purchase of investments (5,539)    
Maturities of investments 450    
Net cash provided by (used in) investing activities (5,125) 12,648  
Effect of exchange rate changes on cash   (1)  
Net increase (decrease) in cash, cash equivalents and restricted cash 4,009 5,541 (52)
Cash, cash equivalents and restricted cash at beginning of year 5,556 15 67
Cash, cash equivalents and restricted cash at end of year $ 9,565 $ 5,556 15
Supplemental Disclosure of Cash Flow Information:      
Interest expense accrued but not yet paid     $ 26